Compare Regeneron Pharmaceuticals Inc (REGN) vs SkyWest Inc (SKYW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs SkyWest Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while SkyWest Inc trades at $96.4 (market cap $3.77B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 18.8× SkyWest Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while SkyWest Inc pays none. Which is the better fit depends on your goals.
| REGN | SKYW | |
|---|---|---|
Market Cap | $70.79B | $3.77B |
Sector | Health | Technology |
52-Week High | $812.27 | $123.72 |
52-Week Low | $545.46 | $78.40 |
Enterprise Value | $64.74B | $5.62B |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
SkyWest (SKYW) trades at $99.34, up 2.17% with a bullish technical signal. The stock shows strong fundamentals with a P/E of 9.52 and net income margin of 10.42%. Recent earnings beat expectations in Q1 2026, and analyst consensus is a buy with a $109.33 price target. The company announced a new president and COO in July 2026, signaling operational focus amid industry fuel cost pressures.
The outlook is positive given undervaluation and earnings momentum, but risks include elevated jet fuel expenses impacting airline profitability. Investor sentiment is supported by institutional buying and lack of sell ratings, though macroeconomic headwinds remain a key watchpoint for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
